Immunomodulation with β-glucan from Pleurotus ostreatus in patients with endocrine-dependent breast cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F22%3A10453990" target="_blank" >RIV/00064165:_____/22:10453990 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/22:10453990
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=L29O-iijHu" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=L29O-iijHu</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2217/imt-2021-0069" target="_blank" >10.2217/imt-2021-0069</a>
Alternative languages
Result language
angličtina
Original language name
Immunomodulation with β-glucan from Pleurotus ostreatus in patients with endocrine-dependent breast cancer
Original language description
Aim: To evaluate the effect of pleuran (β-glucan from Pleurotus ostreatus) administration on the immune profile of patients with endocrine-dependent breast cancer (clinical stages I-II) in clinical and imaging remission. Methodology: Antitumor cellular immunity (CD19+, CD3+, CD4+ and CD8+ T lymphocytes and natural killer cells) of 195 patients (49 in the pleuran group and 146 in the control group) was measured by flow cytometry. Results: We observed a significant increase in the absolute number of CD3+, CD19+, CD4+ and CD8+ T lymphocytes in the pleuran group compared with the control group. Conclusion: Our results suggest potential benefit of continuous pleuran administration on immune rehabilitation of cellular antitumor immunity and better prognosis in breast cancer patients in remission.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/NV19-03-00179" target="_blank" >NV19-03-00179: Fecal microbiota transplantation in cancer patients treated with checkpoint inhibitor therapy.</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Immunotherapy
ISSN
1750-743X
e-ISSN
1750-7448
Volume of the periodical
14
Issue of the periodical within the volume
1
Country of publishing house
GB - UNITED KINGDOM
Number of pages
10
Pages from-to
31-40
UT code for WoS article
000719436400001
EID of the result in the Scopus database
2-s2.0-85121381757